Not Yet RecruitingNot Applicable

A Multicentre Prospective Cohort Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy And Histopathology In India

India4,000 participantsStarted 2026-04-01

Plain-language summary

To estimate the prevalence of histologically confirmed early gastric cancer (EGC) in an Indian multicentre cohort undergoing standardized high-quality upper gastrointestinal endoscopy. EGC is defined as gastric adenocarcinoma confined to the mucosa or submucosa (T1), irrespective of lymph node status, based on histopathology.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Known gastric malignancy.
✕. Prior gastric surgery (excluding H. pylori eradication).
✕. Contraindications to endoscopy or biopsy.
✕. Known hereditary gastric cancer syndromes.

What they're measuring

Prevalence of histologically confirmed early gastric cancer

Timeframe: 2 years

Trial details

NCT IDNCT07486518

SponsorAsian Institute of Gastroenterology, India

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-04-01

Contact for this trial

Dr.Hardik Rughwani Dr.Hardik Rughwani, MBBS, MD, DM

+91-9426928600 hardik.hr@gmail.com

View on ClinicalTrials.gov More Gastric Adenocarcinoma trials